LXRX

+ Watchlist + Portfolio

Lexicon Pharmaceuticals, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.82
52-Week Range: $1.10 – $2.68
Market Cap: $809.82M
P/E (TTM): —
EPS (TTM): -0.16
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 4.64
PEG Ratio: -13.77
Return on Equity: -40.21%
Return on Assets: -14.32%
Gross Margin: 86.02%
Operating Margin: -3835.26%
Profit Margin: -147.38%
Current Ratio: 13.37
Debt/Equity: 0.34
Total Debt: $59.24M
Free Cash Flow: $-44.77M
Revenue Growth: -97.60%
Earnings Growth: —
Enterprise Value: $678.45M

LXRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$139.00K	$1.20M	$31.08M	$49.80M
Cost of Revenue	$0.00	$85.00K	$616.00K	$274.00K
Gross Profit	$139.00K	$1.12M	$30.46M	$49.53M
Research & Development	$52.82M	$58.89M	$84.48M	$61.12M
Selling, General & Admin	$48.08M	$113.98M	$143.10M	$37.32M
Operating Expenses	$100.90M	$172.87M	$227.58M	$98.44M
Operating Income	-$100.76M	-$171.75M	-$197.12M	-$48.91M
EBITDA	-$98.74M	-$163.46M	-$184.29M	-$41.38M
Pretax Income	-$101.94M	-$177.12M	-$200.40M	-$50.34M
Net Income	-$101.94M	-$177.12M	-$200.40M	-$50.34M
Diluted EPS	-0.62	-0.79	-0.63	-0.14
Diluted Shares	165.73M	221.13M	320.03M	363.05M

LXRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$46.34M	$22.46M	$66.66M	$34.33M
Receivables	$28.00K	$1.01M	$3.47M	$2.38M
Inventory	$0.00	$381.00K	$231.00K	$281.00K
Current Assets	$140.87M	$176.55M	$246.19M	$101.89M
Total Assets	$194.30M	$229.43M	$298.42M	$184.99M
Current Liabilities	$23.17M	$31.55M	$45.25M	$20.87M
Long-Term Debt	$48.58M	$99.51M	$100.30M	$49.41M
Total Debt	$55.29M	$106.06M	$108.40M	$62.82M
Total Liabilities	$77.17M	$136.32M	$152.47M	$77.45M
Retained Earnings	-$1.59B	-$1.77B	-$1.97B	-$2.02B
Shareholders' Equity	$117.12M	$93.11M	$145.95M	$107.54M
Working Capital	$117.69M	$145.00M	$200.94M	$81.03M
Net Debt	$2.23M	$77.04M	$33.64M	$19.68M

LXRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$88.85M	-$161.90M	-$178.78M	-$67.85M
Capital Expenditure	-$1.33M	-$470.00K	-$1.03M	—
Free Cash Flow	-$90.18M	-$162.37M	-$179.81M	-$67.85M
Depreciation & Amortisation	$427.00K	$554.00K	$534.00K	$621.00K
Stock-Based Compensation	$11.52M	$14.34M	$13.50M	$12.52M
Investing Cash Flow	-$71.08M	-$49.94M	-$15.38M	$113.02M
Financing Cash Flow	$142.21M	$187.96M	$238.35M	-$48.50M
Share Repurchases	-$864.00K	-$824.00K	-$1.73M	-$572.00K
Net Change in Cash	-$17.72M	-$23.88M	$44.19M	-$3.33M

LXRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.26M	$28.87M	$14.18M	$5.49M	$21.10M	$692.00K
Cost of Revenue	$30.00K	$33.00K	$10.00K	$201.00K	$108.00K	$39.00K
Gross Profit	$1.23M	$28.83M	$14.17M	$5.29M	$20.99M	$653.00K
Research & Development	$15.30M	$15.75M	$18.76M	$11.31M	$12.76M	$17.44M
Selling, General & Admin	$11.61M	$9.35M	$7.60M	$8.76M	$9.23M	$9.75M
Operating Expenses	$26.91M	$25.10M	$26.36M	$20.07M	$21.99M	$27.19M
Operating Income	-$25.68M	$3.74M	-$12.19M	-$14.78M	-$996.00K	-$26.54M
EBITDA	-$23.28M	$5.75M	-$10.46M	-$13.38M	$657.00K	-$29.06M
Pretax Income	-$25.30M	$3.25M	-$12.77M	-$15.53M	-$1.04M	-$31.77M
Net Income	-$25.30M	$3.25M	-$12.77M	-$15.53M	-$1.04M	-$31.77M
Diluted EPS	-0.07	0.01	-0.04	-0.04	0.00	-0.07
Diluted Shares	362.07M	363.57M	363.40M	363.43M	400.24M	437.65M

LXRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$62.89M	$21.36M	$49.66M	$34.33M	$38.09M	$40.92M
Receivables	$47.45M	$2.18M	$2.33M	$2.38M	$11.78M	$1.64M
Inventory	$201.00K	$168.00K	$158.00K	$281.00K	$276.00K	$1.20M
Current Assets	$245.81M	$145.08M	$122.53M	$101.89M	$186.03M	$196.58M
Total Assets	$297.67M	$225.58M	$205.93M	$184.99M	$268.82M	$250.06M
Current Liabilities	$110.69M	$34.84M	$21.72M	$20.87M	$9.90M	$14.71M
Long-Term Debt	$58.64M	$56.11M	$56.51M	$49.41M	$49.68M	$51.44M
Total Debt	$101.74M	$57.02M	$58.15M	$62.82M	$57.71M	$59.28M
Total Liabilities	$174.64M	$96.14M	$85.77M	$77.45M	$65.96M	$75.53M
Retained Earnings	-$1.99B	-$1.99B	-$2.00B	-$2.02B	-$2.02B	-$2.05B
Shareholders' Equity	$123.03M	$129.44M	$120.16M	$107.54M	$202.86M	$174.53M
Working Capital	$135.11M	$110.25M	$100.81M	$81.03M	$176.13M	$181.87M
Net Debt	$37.81M	$34.74M	$6.85M	$19.68M	$11.60M	$10.51M

LXRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$43.78M	$16.99M	-$23.83M	-$17.23M	-$14.73M	-$9.19M
Free Cash Flow	-$43.78M	$16.99M	-$23.83M	-$17.23M	-$14.73M	-$9.19M
Depreciation & Amortisation	$176.00K	$176.00K	$151.00K	$118.00K	$110.00K	$102.00K
Stock-Based Compensation	$3.04M	$3.19M	$3.44M	$2.83M	$3.08M	$3.34M
Investing Cash Flow	$40.58M	$15.48M	$52.13M	$4.83M	-$70.26M	-$16.46M
Financing Cash Flow	-$572.00K	-$45.00M	$0.00	-$2.93M	$88.76M	-$512.00K
Share Repurchases	—	—	—	$0.00	—	—
Net Change in Cash	-$3.77M	-$12.52M	$28.29M	-$15.33M	$3.76M	-$26.16M

Market Snapshot

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing precision medicines for serious chronic conditions. The company markets Xermelo for carcinoid syndrome diarrhea and has a pipeline addressing cardiovascular, metabolism, and other therapeutic areas. Lexicon utilizes its proprietary gene knockout technology platform to identify and validate novel drug targets.